Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CELO, QNT Prepared to Change Things for the Better

CELO, QNT Prepared to Change Things for the Better

CoineditionCoinedition2024/02/29 14:55
By:Victor Olanrewaju

Discover Crypto said CELO and QNT’s fundamentals and community could drive the prices higher. Higher volatility alongside buying pressure could push CELO above $1. QNT’s 4-hour chart displayed a golden cross that could lead it to $120.

  • Discover Crypto said CELO and QNT’s fundamentals and community could drive the prices higher.
  • Higher volatility alongside buying pressure could push CELO above $1.
  • QNT’s 4-hour chart displayed a golden cross that could lead it to $120.

According to the Discover Crypto YouTube channel, Celo (CELO) and Quant (QNT) are two altcoins that have not reached their full potential and might be ready to do so in the coming week.

However, the channel did not come to this conclusion without giving its reasons. For CELO, Discover Crypto noted that its volume has been surging compared to what it was some months back. The increase in volume suggests, rising interest in the project. If this continues, CELO’s price could jump.

In QNT’s case, the channel focused on the fundamentals. According to them, Quant’s place as an enterprise solution for financial institutions makes it a project whose token could experience high demand. They also noted that QNT has a strong community which could help drive a rally.

Celo (CELO)

The 4-hour CELO/USD chart showed that the cryptocurrency experienced inconsistencies despite its price increase. At press time, CELO’s price was $0.97. However, a look at the Aroon indicator revealed that bulls and bears seemed to be at war concerning the side to control the price action.

As of this writing, the Aroon Down (blue) was 71.43% while the Aroon Up (orange) was 64.29%. A position like this suggests that CELO could end up consolidating. If bulls eventually take control, CELO’s price might hit $1.

CELO, QNT Prepared to Change Things for the Better image 0 CELO, QNT Prepared to Change Things for the Better image 1 CELO/USD 4-Hour Chart (Source: TradingView )

On the other hand, bearish dominance could force a decline below $0.85. Furthermore, Coin Edition evaluated the Bollinger Bands (BB), which indicated a dearth of price fluctuations. With the BB condition, CELO’s price might not experience a massive hike soon. However, if volatility spikes going forward, the token value might extend much higher than $1.

Quant (QNT) 

QNT’s 4-hour chart mirrored a situation where bears were pulling back the upswing at any given opportunity. However, QNT was inches away from hitting $115.  At press time, the 9 EMA (blue) had crossed over the 20 EMA (yellow), indicating a bullish short-term bias.

As long as QNT stays above the golden cross ($104.43), the price could rise higher. Conversely, if the 20 EMA flips the 9 EMA, the bullish thesis could be invalidated. In this case, QNT’s price might retrace close to $100.

CELO, QNT Prepared to Change Things for the Better image 2 CELO, QNT Prepared to Change Things for the Better image 3 QNT/USD 4-Hour Chart (Source: TradingView )

In a highly bullish scenario, QNT’s price might rally above $120. However, a downward reversal remains an option in the short term. Meanwhile, the long-term potential for the token looks bright if the aforementioned fundamentals remain relevant.

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs